Quarterly ResultAug 13, 2026, 04:21 PM
Yarrow Bioscience Q2 2026 Net Loss $(6.51)M; Cash $18.67M
AI Summary
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) reported a net loss of $(6.51) million for the second quarter of 2026 and $(9.26) million for the first half of 2026. The company, which recently completed a merger with Pre-Merger Yarrow, ended the quarter with $18.67 million in cash and cash equivalents. Yarrow also announced the initiation of a combined Phase 2a/Phase 2b trial for its lead product candidate, YB-101, in patients with Graves' disease.
Key Highlights
- Net loss for Q2 2026 was $(6.51) million, and $(9.26) million for H1 2026.
- Research and development expenses were $4.94 million for Q2 2026.
- General and administrative expenses were $1.76 million for Q2 2026.
- Cash and cash equivalents stood at $18.67 million as of June 30, 2026.
- Accumulated deficit reached $(80.25) million as of June 30, 2026.
- The company initiated a combined Phase 2a/Phase 2b trial for YB-101 in Graves' disease in June 2026.
- The merger with VYNE Therapeutics Inc. was accounted for as a reverse recapitalization with an exchange ratio of 0.7171.
Price Impact
More from VYNE